Stemson Therapeutics hair follicle neogenesis
Grew entirely new follicles from induced pluripotent stem cells, and ran out of money before reaching a clinical trial.
This programme is no longer being actively pursued.
- Developed by
- Stemson Therapeutics
- Current phase
- Discontinued
- Indications
- Androgenetic alopecia
- Also known as
- Stemson
- Last public activity
- Never
- Record confidence
- Medium
Development stopped.
Why it matters
This category — building new follicles rather than rescuing existing ones — is the only route that could restore hair to a fully bald scalp. It is also the furthest from the clinic, and Stemson is why this register keeps failures: it ceased operations in late 2024 without ever reaching a first-in-human trial, reportedly for want of funding rather than because of any scientific result, and the domain it used now hosts an unrelated hair-care blog. Note the sourcing — the company was private, so there is no filing to point at and this rests on trade press, which is why the row is not marked HIGH. Apply the same scepticism to every timeline you read for the rest of this category.
Development history
No phase changes recorded yet.
Registered trials
Pulled automatically from ClinicalTrials.gov. Matching is by name and development code, so occasional gaps are possible — tell us if you spot one.
No trials matched to this programme in ClinicalTrials.gov.
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first.
Sources
- Stemson Therapeutics Shuts Down — Press